ORGENESIS INC (ORGS)
US68619K2042 - Common Stock
Overall ORGS gets a fundamental rating of 1 out of 10. We evaluated ORGS against 565 industry peers in the Biotechnology industry. Both the profitability and financial health of ORGS have multiple concerns. ORGS has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ORGS had negative earnings in the past year.
In the past year ORGS has reported a negative cash flow from operations.
In the past 5 years ORGS reported 4 times negative net income.
In the past 5 years ORGS always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ORGS (-124.09%) is worse than 81.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -124.09% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-142.32%
ROA(5y)-90.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ORGS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ORGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ORGS has been increased compared to 1 year ago.
The number of shares outstanding for ORGS has been increased compared to 5 years ago.
The debt/assets ratio for ORGS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -12.18, we must say that ORGS is in the distress zone and has some risk of bankruptcy.
ORGS has a worse Altman-Z score (-12.18) than 79.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.18 |
ROIC/WACCN/A
WACC7.32%
2.3 Liquidity
ORGS has a Current Ratio of 0.07. This is a bad value and indicates that ORGS is not financially healthy enough and could expect problems in meeting its short term obligations.
ORGS has a Current ratio of 0.07. This is amonst the worse of the industry: ORGS underperforms 98.76% of its industry peers.
ORGS has a Quick Ratio of 0.07. This is a bad value and indicates that ORGS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.07, ORGS is not doing good in the industry: 98.76% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.07 | ||
| Quick Ratio | 0.07 |
3. Growth
3.1 Past
ORGS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -125.83%.
Looking at the last year, ORGS shows a very negative growth in Revenue. The Revenue has decreased by -98.14% in the last year.
Measured over the past years, ORGS shows a very negative growth in Revenue. The Revenue has been decreasing by -50.95% on average per year.
EPS 1Y (TTM)-125.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.75%
Revenue 1Y (TTM)-98.14%
Revenue growth 3Y-58.93%
Revenue growth 5Y-50.95%
Sales Q2Q%-96.47%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y190.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ORGS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 3.39, which indicates a rather cheap valuation of ORGS.
ORGS's Price/Forward Earnings ratio is rather cheap when compared to the industry. ORGS is cheaper than 99.29% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.50. ORGS is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.39 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ORGS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ORGS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ORGENESIS INC
NASDAQ:ORGS (10/18/2024, 8:00:02 PM)
After market: 2.25 +0.14 (+6.64%)2.11
-1.13 (-34.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.06M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.39 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -124.09% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.07 | ||
| Quick Ratio | 0.07 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-125.83%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y190.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-98.14%
Revenue growth 3Y-58.93%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y